Rhopressa for Corneal Edema Associated With Fuchs Dystrophy

Prospective Randomized Study to Determine Whether Use of Rhopressa™ Can Ameliorate Corneal Edema Associated With Fuchs Dystrophy

NCT04051463•Price Vision Group

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Fuchs Endothelial Dystrophy

Interventions

Netarsudil Ophthalmic Solution

Placebo

Locations

United States

Locations (1)

Price Vision Group

Indianapolis, Indiana, United States

Key Dates

Start Date

August 5, 2019

Primary Completion Date

July 1, 2020

Completion Date

July 1, 2020

Last Updated

October 19, 2021

Sponsors

Lead Sponsor

Price Vision Group

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 19, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions